reports
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 70,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment in accordance with Nasdaq Listing rule 5635(c)(4). The stock o...
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncolog...
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio -Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz’s pipeline- -Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) and Chimerix (Nasdaq: CMRX) (“Chimerix”), today announced the companies have entered into a definit...
- David Nierengarten
- Dennis Pak
- Martin Fan
Fulcrum Therapeutics to Participate in the Leerink Partners Global Hea...
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on March 11, 2025 at 8:40 am ET. The webcast of the fireside chat will be accessible and by visiting t...
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
O REALTY INCOME CORPORATION
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
LOW LOWE'S COMPANIES INC.
KURA KURA ONCOLOGY INC.
HD HOME DEPOT INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CRM SALESFORCE.COM INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BBY BEST BUY CO. INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
AAP ADVANCE AUTO PARTS INC.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
EPRT ESSENTIAL PROPERTIES REALTY TRUST
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
PLTR PALANTIR TECHNOLOGIES
VRDN VIRIDIAN THERAPEUTICS INC
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
FNMA FEDERAL NATIONAL MORTGAGE ASSOCIATION
ELEV ELEVATION ONCOLOGY
APP APPLOVIN CORP
UWMC UWM HLDGS CORP
ATXS ASTRIA THERAPEUTICS INC
AVTE AEROVATE THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
NTST NETSTREIT CORP
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
BNL BROADSTONE NET LEASE INC
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Robert Driscoll
- Yun Zhong
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
ATXS ASTRIA THERAPEUTICS INC
AVTE AEROVATE THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
Fulcrum Therapeutics Announces Recent Business Highlights and Financia...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 ― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended 2024 with $241.0 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (...
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financi...
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 25, 2025, before the U.S. financial markets open. Manageme...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on February 12, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 270,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4). The s...
Chimerix Announces FDA Acceptance and Priority Review of New Drug Appl...
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Potential First Approval for Patients with Recurrent H3 K27M-mutant Diffuse Glioma PDUFA Target Action Date of August 18, 2025 No Advisory Committee Meeting Currently Planned to Discuss Application DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced ...
- David Nierengarten
- Dennis Pak
- Martin Fan
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Ru...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an...
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Hea...
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 at 1:20 pm ET. The webcast of the fireside chat will be acces...
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposi...
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, and Tom Riga, Chief Operating and Commercial Officer, will participate in a fireside chat at the JonesTrading Virtual Precision Medicine Symposium on Monday, February 3, 2025 at 11:00 a.m. ET. An audio webcast of the panel discussion w...
- Jonathan Moreland
NEOG NEOGEN CORPORATION
LAKE LAKELAND INDUSTRIES INC.
CTSO CYTOSORBENTS
CDXS CODEXIS
ASA ASA
ADC AGREE REALTY CORPORATION
WVE WAVE LIFE SCIENCES
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
ZIVO INC.
ETST ZIVO BIOSCIENCE
FUND INC.
ANIX EARTH SCIENCE TECH
LBSRD ROYCE FOCUS TRUST
ETON INC.
GRX ANIXA BIOSCIENCES
MCFT LIBERTY STAR URANIUM & METALS
PGNY ETON PHARMACEUTICALS
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
DCTH MASTERCRAFT BOAT HOLDINGS
ENX PROGYNY
PRLD PENNANT GROUP
NVCT DELCATH SYSTEMS
ANEB EATON VANCE NEW YORK MUNICIPAL BOND FUND
IBRX PRELUDE THERAPEUTICS
BHVN NUVECTIS PHARMA INC
ACXP ANEBULO PHARMACEUTICALS INC
BUKS IMMUNITYBIO INC
GLSI BIOHAVEN LTD
MEGI ACURX PHARMACEUTICALS INC
CVI BUTLER NATIONAL CORP
SRFM GREENWICH LIFESCIENCES INC
OCX MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
AVDL CVR ENERGY
MXF INC.
TXO SURF AIR MOBILITY INC.
TTGT ONCOCYTE CORPORATION
AMST AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
WHLM THE MEXICO FUND
IBIO INC.
SDHY MORNINGSTAR PARTNERS
BATRK L.P.
MYCB TECHTARGET INC.
AMESITE INC.
WILHELMINA INTERNATIONAL INC
IBIO INC.
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on January 17, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to six new employees of non-statutory stock options to purchase up to a total of 355,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule 5635(c)(4). The ...
Moody's Ratings upgrades Golub Capital BDC, Inc.'s senior unsecured ra...
Moody's Ratings (Moody's) has upgraded the long-term issuer and senior unsecured ratings of Golub Capital BDC, Inc. (GBDC) to Baa2 from Baa3. We also upgraded GBDC's senior unsecured shelf rating to (P)Baa2 from (P)Baa3. Following the upgrade, the outlook was changed to stable from positive. RATIN...
- Jonathan Moreland
OMEX ODYSSEY MARINE EXPLORATION INC.
NEOG NEOGEN CORPORATION
LNDC LANDEC CORP.
CDXS CODEXIS
ASA ASA
NEWT NEWTEK BUSINESS SERVICES INC.
ADC AGREE REALTY CORPORATION
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
DMLP DORCHESTER MINERALS L.P.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
COGT COGINT
ZIVO INC.
ETST ZIVO BIOSCIENCE
LOVE INC.
FUND EARTH SCIENCE TECH
ANIX LOVESAC
LBSRD ROYCE FOCUS TRUST
ETON INC.
GRX ANIXA BIOSCIENCES
MCFT LIBERTY STAR URANIUM & METALS
PGNY ETON PHARMACEUTICALS
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
DCTH MASTERCRAFT BOAT HOLDINGS
ENX PROGYNY
PRLD PENNANT GROUP
NOTV DELCATH SYSTEMS
NVCT EATON VANCE NEW YORK MUNICIPAL BOND FUND
ANEB PRELUDE THERAPEUTICS
BHVN INOTIV
ACXP INC.
BUKS NUVECTIS PHARMA INC
GLSI ANEBULO PHARMACEUTICALS INC
MEGI BIOHAVEN LTD
CVI ACURX PHARMACEUTICALS INC
SRFM BUTLER NATIONAL CORP
OCX GREENWICH LIFESCIENCES INC
AVDL MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
TXO CVR ENERGY
MRKR INC.
TTGT SURF AIR MOBILITY INC.
DTIL ONCOCYTE CORPORATION
AMST AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
WHLM MORNINGSTAR PARTNERS
IBIO L.P.
SDHY MARKER THERAPEUTICS INC
TECHTARGET INC.
PRECISION BIOSCIENCES INC.
AMESITE INC.
WILHELMINA INTERNATIONAL INC
IBIO INC.
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
Chimerix to Speak Today at The White House Cancer Moonshot Forum
Chimerix to Speak Today at The White House Cancer Moonshot Forum Chief Scientific Officer, Joshua E. Allen, Ph.D. to Highlight Cancer Moonshot’s Impact on Brain Cancer and Rare Pediatric Disease Drug Development DURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced today that Dr. Joshua E. Allen, Chief Scientific Officer at Chimerix, will speak at the Biden Cancer Moonshot Mission Report 2024 – And Beyond. D...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.